Production / Operations Neutral

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption

Restart Life Validates Acquired Asset But Integration Headwinds Persist

By The Northwire Desk — AI Analysis Apr 23, 2026 · 08:01 HEAL · 0.09 Restart Life Sciences Corp.

Executive Summary

Most Recent Release (April 23, 2026): Holy Crap Foods Inc., a wholly owned subsidiary acquired in February 2026, reports cumulative sales of over 500,000 units between January 2023 and March 2026.
Sales Velocity: Approximately 165,000+ units per year or 13,800+ units per month.
Expansion Strategy: Moving beyond Canada into the United States and Caribbean markets (Bermuda placement noted).
Product Portfolio: Leveraging gut health success to expand into cognitive health products (BrainQ™, BrainBalls™).
Operational Capacity: Infrastructure established to support increased production volumes.
Contextual Preceding News (April 22, 2026): March 2026 performance showed a decrease in total brand sales compared to March 2025 ($126,348 vs $147,139), despite record Amazon Canada sales.
Financing History: Raised ~$1.13M via private placement (Dec 2025) and $250k loan with warrants (Mar 2026). Acquisition of Holy Crap closed Feb 27, 2026 for $1M cash.

Material Impact

Validation vs. Growth: The 500,000 unit milestone is largely cumulative data from before Restart Life Sciences acquired the company (Jan 2023 to Jan 2026). It validates the asset's historical viability but does not confirm Restart's management has successfully accelerated growth post-acquisition.
Revenue Trend Concern: The immediate preceding operational update (April 22) revealed a year-over-year sales decline in March ($147k vs $126k). This contradicts the "Strong Consumer Adoption" narrative slightly, suggesting channel realignment costs or integration friction may be suppressing top-line growth temporarily.
Dilution Risk: The company has issued significant warrants (2.5M from loan + 10M+ from private placements) at $0.10 exercise price. With the current trading price at $0.09, these are underwater, reducing immediate dilution risk but signaling capital structure complexity.
Capital Efficiency: The acquisition cost ($1M cash) was funded by recent financing proceeds. While it added >$1M annualized revenue per Feb announcement, March performance suggests the run rate may be lower than projected during integration.
Market Expectations: This news is consistent with previous announcements regarding the Holy Crap asset's scale. It does not introduce new financial upside or strategic pivots that were not already priced in following the February acquisition closing.

HEAL · Price

Company Overview

Company: Restart Life Sciences Corp. (CSE: HEAL implied).
Flagship Project/Asset: Holy Crap Foods Inc. (Acquired Feb 2026).
Business Model: Consumer health foods focusing on gut health (Holy Crap Cereal) and cognitive wellness (BrainQ, BrainBalls).
Operations: Turnkey manufacturing facility in Gibsons, BC; distribution across Canada with expansion plans for US/Caribbean.
Development Stage: Post-acquisition integration phase; moving from "project" to "revenue-generating subsidiary."

More from Restart Life Sciences Corp.